Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 257.00K |
Gross Profit | 0.00 | -44.26M | -167.00K | -367.00K | 221.96K |
EBITDA | -103.07M | -59.13M | -37.90M | -40.37M | -47.44M |
Net Income | -95.88M | -54.70M | -38.95M | -45.30M | -51.10M |
Balance Sheet | |||||
Total Assets | 212.88M | 177.56M | 139.78M | 176.60M | 97.75M |
Cash, Cash Equivalents and Short-Term Investments | 196.33M | 162.32M | 125.88M | 161.17M | 82.19M |
Total Debt | 26.73M | 26.49M | 26.14M | 25.79M | 25.28M |
Total Liabilities | 41.43M | 37.19M | 32.00M | 32.10M | 33.36M |
Stockholders Equity | 171.45M | 140.37M | 107.78M | 144.50M | 64.38M |
Cash Flow | |||||
Free Cash Flow | -89.11M | -51.36M | -34.56M | -40.14M | -43.13M |
Operating Cash Flow | -89.09M | -51.06M | -34.55M | -40.08M | -39.84M |
Investing Cash Flow | -39.94M | -57.12M | 52.65M | -69.46M | 9.05M |
Financing Cash Flow | 117.58M | 82.78M | 87.00K | 120.81M | 3.69K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $760.91M | 55.18 | 33.47% | ― | 29.77% | ― | |
61 Neutral | $873.21M | ― | -452.20% | ― | 8.98% | 6.32% | |
60 Neutral | $589.60M | ― | -37.13% | ― | -38.14% | 29.69% | |
53 Neutral | $545.98M | ― | -35.41% | ― | ― | ― | |
52 Neutral | $7.47B | 0.53 | -62.70% | 2.38% | 14.92% | 0.82% | |
47 Neutral | $551.48M | ― | -41.84% | ― | ― | 3.95% | |
46 Neutral | $452.83M | ― | -75.77% | ― | ― | -44.25% |
On March 26, 2025, Savara announced a loan agreement with Hercules Capital for up to $200 million, aimed at strengthening its financial position following the submission of a Biologics License Application to the FDA for MOLBREEVI, a potential first-in-class therapy for aPAP. The agreement includes an initial $30 million to refinance existing debt, with additional funds contingent on FDA approval and other milestones, supporting Savara’s efforts to commercialize MOLBREEVI in the U.S. and Europe.